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Molecular  signaling  pathways  are  promising 
targets in cancer therapy, but resistance often 
thwarts clinical success. Acquired mutations of 
drug targets, feedback activation of oncogenic 
signals, and redundant signaling pathways are 
important causes of resistance, and cocktails of 
multiple inhibitors are considered one potential 
solution (Sawyers, 2007). For example, the rapa­
mycin analogues (rapalogs) are potent inhibi­
tors of mTORC1 with promising antitumor 
activity against some cancers (Dancey, 2010). 
mTORC1  blockade  by  rapamycin  interferes 
with the activation of cap­dependent transla­
tion and exploits a cancer cell’s dependence on 
increased  translation  of  certain  oncoproteins 
(Wendel et al., 2007; Sonenberg and Hinnebusch, 
2009). In animal models, rapamycin dramatically 
enhances  the  effectiveness  of  DNA­damaging 
chemotherapy (Wendel et al., 2004). However,   
in clinical trials in non­Hodgkin’s lymphoma 
(NHL), rapalogs have failed to show durable 
clinical benefit for most patients (Dancey et al., 
2009; Hess et al., 2009; Smith et al., 2010). The 
causes are ill­understood, and new insight should 
enable better therapies.
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New anticancer drugs that target oncogenic signaling molecules have greatly improved the 
treatment of certain cancers. However, resistance to targeted therapeutics is a major 
clinical problem and the redundancy of oncogenic signaling pathways provides back-up 
mechanisms that allow cancer cells to escape. For example, the AKT and PIM kinases pro-
duce parallel oncogenic signals and share many molecular targets, including activators of 
cap-dependent translation. Here, we show that PIM kinase expression can affect the clini-
cal outcome of lymphoma chemotherapy. We observe the same in animal lymphoma models. 
Whereas chemoresistance caused by AKT is readily reversed with rapamycin, PIM-mediated 
resistance is refractory to mTORC1 inhibition. However, both PIM- and AKT-expressing 
lymphomas depend on cap-dependent translation, and genetic or pharmacological blockade 
of the translation initiation complex is highly effective against these tumors. The therapeu-
tic effect of blocking cap-dependent translation is mediated, at least in part, by decreased 
production of short-lived oncoproteins including c-MYC, Cyclin D1, MCL1, and the PIM1/2 
kinases themselves. Hence, targeting the convergence of oncogenic survival signals on 
translation initiation is an effective alternative to combinations of kinase inhibitors.
© 2011 Schatz et al.  This article is distributed under the terms of an Attribution–
Noncommercial–Share Alike–No Mirror Sites license for the first six months after 
the publication date (see http://www.rupress.org/terms). After six months it is 
available under a Creative Commons License (Attribution–Noncommercial–Share 
Alike 3.0 Unported license, as described at http://creativecommons.org/licenses/
by-nc-sa/3.0/).
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and Table S2). The same analyses of 116 DLBCL patients treated 
between 1989 and 2008 showed differences that did not reach   
statistical significance in OS (P = 0.1678) or TTE (P = 0.4461; 
Fig. 1, H and I; and Table S3). Similarly, another group re­
cently reported association of PIM2 with outcome in DLBCL 
(Gómez­Abad et al., 2011). All but three of the DLBCL pa­
tients  were  treated  with  upfront  chemotherapy,  including 
doxorubicin in 88% of patients. Statistical analyses for each PIM 
kinase analyzed as a single variable or coexpression of PIM1/2 
in FL and DLBCL are available in Table S4 and Table S5.
PIM promotes the development of drug-resistant  
lymphomas in vivo
To study the function of PIM kinase activity in lymphomas, 
we modeled its effects in murine models of aggressive pre–B 
cell (Adams et al., 1985) and indolent follicular lymphoma 
(Egle  et  al.,  2004).  In  brief,  we  used  adoptive  transfer  of   
Eµ-Myc  or VavP­Bcl2  transgenic  hematopoietic  progenitor 
cells (HPCs; Wendel et al., 2004) expressing AKT, Pim2, or 
vector into lethally irradiated, syngeneic wild­type recipients 
and monitored the animals for lymphomas (Fig. 2 A). PIM1 
and PIM2 are highly homologous, therefore we did not ex­
amine  PIM1  separately  (Nawijn  et  al.,  2011).  Both  Pim2  
(n = 12; P < 0.0001) and AKT (n = 30; P < 0.0001) accelerated 
disease onset compared with controls (n = 64; P = 0.1209 
Pim2 vs. AKT; Fig. 2 A; Verbeek et al., 1991; Wendel et al., 
2004). Immunoblotting confirmed expression of AKT and 
Pim2 and translational activation by both kinases as indicated 
by increased phosphorylation of 4E­BP1 and ribosomal pro­
tein S6 (Fig. 2 C). Histopathology and surface marker analysis 
revealed that Pim2­ and AKT­expressing tumors were indis­
tinguishable from aggressive pre–B cell lymphomas (Fig. 2 B 
and unpublished data). The VavP­Bcl2 model is a genetically 
and pathologically accurate model of FL, and both Pim2  
(P < 0.0001) and AKT (P = 0.0292) accelerated development 
compared with vector of a slowly proliferating B cell lymphoma 
with splenic involvement and increased peripheral lympho­
cyte counts (unpublished data). Hence, Pim2 and AKT acti­
vate  protein  translation  and  promote  lymphomagenesis  in 
mouse models of aggressive and indolent lymphoma.
Next, we examined how PIM and AKT affect treatment 
responses in vivo. In brief, we transplanted aggressive Eµ-Myc 
lymphomas with defined genetic alterations into nonirradi­
ated recipients, and then treated with 10 mg/kg doxorubicin 
once lymphomas had developed (Wendel et al., 2004). A side­ 
by­side comparison of chemosensitive Eµ-Myc/Arf/ tumors 
(control; n = 44) with Eµ-Myc/Pim2 (n = 6), or Eµ-Myc/AKT  
(n = 30) lymphomas, revealed early relapse and shortened sur­
vival with Pim2­ and AKT­expressing tumors (Fig. 2 D; P = 
0.0145 Pim2 vs. Arf, P<0.0001 AKT vs. Arf). Rapamycin 
alone had little effect on any tumor (Fig. 2 E). However, combi­
nations of rapamycin with doxorubicin caused dramatic re­
sponses in AKT lymphomas, but had no effect on Pim2­expressing 
tumors (Pim2, n = 13; AKT, n = 21; control, n = 28; P < 0.0001, 
Pim vs. AKT; Fig. 2 F). Hence, chemoresistance caused by AKT 
but not by Pim2 is readily reversed by mTORC1 inhibition.
Multiple  oncogenic  signaling  pathways  cause  aberrant   
activation of protein translation in cancer cells, including RAS, 
PI3K–AKT, MAPK, and the PIM kinases (Sonenberg and 
Hinnebusch, 2009). The PIM kinases were identified in a ge­
netic screen. They promote cell growth and survival and share 
many targets, including regulators of protein translation, with 
the better studied AKT/PKB kinases (Nawijn et al., 2011). 
PIM kinases are induced by cytokine signals and, unlike AKT 
do  not  require  posttranslational  modifications  for  activity 
(Fox et al., 2003). Activation of cap­dependent translation via 
derepression of the translation factor eIF4E is a critical output 
of both AKT and PIM signaling in cancer (Wendel et al., 
2004; Hammerman et al., 2005). PIM1 and PIM2 are widely 
expressed in cancer; PIM3 is restricted to certain solid tumors 
(Nawijn et al., 2011). Accordingly, PIM inhibitors have been 
developed, but clinical trials were terminated early because of 
cardiac  toxicity  (Morwick,  2010).  Our  study  explores  the 
clinical impact of PIM1/2 expression in NHL, and we demon­
strate that inhibition of cap­dependent translation is an effec­
tive therapy alternative to combinations of kinase inhibitors.
RESULTS AND DISCUSSION
PIM1 and PIM2 are widely expressed in NHL and affect  
the outcome of follicular lymphoma (FL)
We found widespread expression of PIM1 and PIM2 across 
multiple subtypes of NHL. Immunohistochemical staining of 
tissue microarrays (TMA) reveals that PIM1 is expressed in 
87% of mantle cell lymphomas (MCL; Hsi et al., 2008), 76% 
of  chronic  lymphocytic  leukemia/small  lymphocytic  lym­
phoma (CLL/SLL; Chen et al., 2009), and 48 and 42% of dif­
fuse large B cell lymphoma (DLBCL) and FL, respectively. 
PIM2 is detected in 42% of DLBCL and between 24% and 
30% of FL, MCL, and CLL/SLL (Fig. 1, A–E; and Table S1). 
Similarly, PIM1/2 mRNA levels are highly expressed in the 
activated B cell (ABC) type, rather than the germinal center 
(GC) type of DLBCL (Alizadeh et al., 2000; Rosenwald et al., 
2003; Basso et al., 2005; Lenz et al., 2008; unpublished data). 
PIM2 is abundantly expressed across a panel of human lym­
phoma cell lines, whereas PIM1 is coexpressed in some, and 
immunoblots on mouse pro–B cells and Eµ­Myc lymphomas 
confirm PIM1/2 induction by cytokine signals (Fox et al., 
2003; unpublished data).
PIM expression affects the outcome of therapy in follic­
ular lymphoma patients. First, we analyzed pretreatment follic­
ular lymphoma samples from 66 patients treated at Memorial 
Sloan­Kettering Cancer Center (MSKCC) between 1984 
and 2000 (Table S2). All but five of these patients received 
chemotherapy, including doxorubicin in 61% of patients. In 
this cohort, time to event (TTE) and overall survival (OS) 
were  significantly  better  for  patients  whose  tumors  were 
PIM­negative (PIM, no PIM1 or PIM2) compared with 
patients  whose  tumors  were  PIM­positive  (PIM+,  PIM1, 
PIM2, or both; P = 0.0113 for TTE, P = 0.0372 for OS for 
PIM+ vs. PIM tumors). The mean age was 60.9 and 52.6 yr 
for the groups, respectively; however, age alone did not ex­
plain the difference in outcome (P = 0.13; Fig. 1, F and G;   JEM Vol. 208, No. 9  1801
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are rapidly enriched under rapamycin treatment (Fig. 3, A and 
inset). Pim2 causes partially rapamycin­insensitive increases 
in the phosphorylation of 4E­BP1, eIF4E, and Bad, whereas 
S6 phosphorylation remains sensitive to rapamycin (Fig. 3 B). 
The cap­binding protein eIF4E is the rate­limiting factor in 
cap­dependent translation that is activated by phosphoryla­
tion of its inhibitor 4E­BP1 and can be further enhanced by 
direct eIF4E (S209) phosphorylation (Wendel et al., 2007; 
Sonenberg and Hinnebusch, 2009). Profiles of ribosome load­
ing on mRNAs (polysome profiles) indicate the efficiency of 
protein translation. Polysome profiles on parental and Pim2­
expressing EµMyc/Tsc2/ lymphoma cells reveal a partially 
rapamycin­refractory increase of protein 
translation  in  Pim­expressing  lym­
phomas (Fig. 3 C). Accordingly, both 
Pim  and  direct  expression  of  eIF4E 
protect against rapamycin and have a 
similar effect in cells treated with the 
TOR  kinase  inhibitors  PP­242  and 
Torin1 (Feldman et al., 2009; Thoreen 
et al., 2009; Fig. 3 D). By comparison, 
a small hairpin RNA (shRNA) against 
BAD showed no protective effect dur­
ing rapamycin treatment (unpublished 
data).  To  examine  whether  PIM­ 
expressing  tumors  remained  depen­
dent on cap­dependent translation, we 
tested  the  antiproliferative  effects  of   
a  constitutively  active  inhibitor  of 
eIF4E (4E-BP1-4A) that acts down­
stream from mTORC1 (Rong et al., 
2008). Surprisingly, parental Eµ-Myc/
Tsc2/  lymphomas  and  Pim2  ex­
pressing  Eµ-Myc/Tsc2/  cells  were 
equally sensitive to direct inhibition of 
eIF4E  and  cells  expressing  4E­BP1/
GFP  were  rapidly  depleted  from   
a  mixed  population,  but  had  little   
effect in nontransformed cells (Fig. 3 E 
and unpublished data). Hence, PIM2 
readily bypasses mTORC1 inhibition, 
but  is  unable  to  protect  lymphoma 
cells from the effects of direct transla­
tion inhibition.
PIM-expressing lymphomas remain dependent on eIF4E  
and cap-dependent translation
We examined how PIM bypasses mTORC1 inhibition in   
rapamycin­sensitive Eµ-Myc/Tsc2/ lymphomas (Mills et al., 
2008). TSC2 is the Rheb GTPase­activating protein and acts 
as a negative regulator of mTORC1 activation by Rheb (Tee 
et al., 2003; Mavrakis et al., 2008). Accordingly, tumors arising 
in Tsc2 deficient animals show an mTORC1­dependent and 
rapamycin­sensitive activation of cap­dependent translation. 
Pim2 expression in Eµ-Myc/Tsc2/ cells abrogates rapamy­
cin sensitivity, and in mixed populations of parental and Pim2/
GFP­expressing Eµ-Myc/Tsc2/ cells the Pim2/GFP cells 
Figure 1.  PIM kinase expression affects 
the outcome of lymphoma therapy. (A and 
B) DLBCL TMAs stained for PIM1 (A) and PIM2 
(B). (C and D) Representative tumor cores for 
each PIM histology score (0–2). (E) Pie graphs 
showing breakdown of PIM1/2 TMA scores by 
disease; see also Table S1. (F) TTE analysis 
after primary therapy in follicular lymphoma 
(n = 66). (G) OS analysis from date of diagno-
sis in follicular lymphoma. (H and I) TTE (H) 
and OS (I) in DLBCL (n = 116).1802 Targeting survival signals in lymphoma | Schatz et al.
absence of translational activation (Wendel et al., 2004; Fig. 4 C). 
Moreover, silvestrol is also far superior to two recently devel­
oped PIM inhibitors in human lymphoma cells. In brief, we 
tested SGI­1776, the only PIM inhibitor that has entered 
clinical trials (biochemical IC50 for PIM1, 15 nM; PIM2, 363 
nM),  and  SGI­1773  (biochemical  IC50  for  PIM1,  2  nM; 
PIM2, 43 nM); both drugs were developed and supplied to us 
by SuperGen Inc. (Morwick, 2010). The PIM kinase inhibi­
tors induced cell death in various human lymphoma cells at 
concentrations between 1–10 µM; in comparison, silvestrol 
had the same cell kill at 1–10 nM (Fig. 4 D). In animals, sil­
vestrol was able to reverse Pim2­mediated rapamycin resistance 
Silvestrol is a small molecule inhibitor of cap- 
dependent translation
Silvestrol was identified in a screen for inhibitors of eIF4A, 
the RNA helicase component of the translation initiation 
complex  that  is  thought  to  unwind  an  mRNA’s  5UTR 
(Bordeleau et al., 2008). Consistent with our genetic data   
using a constitutive 4E-BP1 construct, we found that Pim2 is 
unable to protect Eµ-Myc/Tsc2/ cells from silvestrol alone 
or in combination with rapamycin (Figs. 4, A andB). Silvestrol 
kills parental and Pim2­expressing Eµ-Myc/Tsc2/ cells at 
nanomolar concentrations in vitro, but is inactive against 3T3 
fibroblasts and Myc/Bcl2 lymphomas tumors that arise in the 
Figure 2.  Pim2 and AKT in a mouse lymphoma model. (A) Eµ-Myc HPCs expressing Pim2, AKT, or vector were transplanted into lethally irradiated syn-
geneic wild-type mice. Tumor onset in Pim2 (green; n = 12), AKT (red; n = 30) and vector (black; n = 64 recipients). (B) Histological and immunohistochemical 
analyses of indicated Eµ-Myc lymphomas. Bar, 20 µm. (C) Immunoblot analyses of indicated Eµ-Myc lymphomas. (D–F) Time to relapse in animals bearing  
Eµ-Myc/Arf/ (control, black line), Eµ-Myc/Pim2 (green), and Eµ-Myc/AKT (red) lymphomas treated with doxorubicin (D; control, n = 44; Pim2, n = 6; AKT,  
n = 30) or rapamycin (E; control, n = 27; Pim2, n = 7; AKT, n = 18) or a combination of both drugs (F; control, n = 28; Pim2 ,n = 13; AKT, n = 21).JEM Vol. 208, No. 9  1803
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oncoproteins  including  c-MYC,  MCL1  and  Cyclin  D1 
(Sonenberg  and  Hinnebusch,  2009).  Treatment  of  PIM­ 
expressing human lymphoma cells with the PIM inhibitor 
SGI­1773 (10 µM) somewhat reduced Cyclin D1, but had no 
effect on c-MYC or MCL1 (Fig. 4 F). In contrast, silvestrol 
(10 nM) caused almost complete loss of Cyclin D1, c-MYC, 
and MCL1. Moreover, silvestrol completely ablated the ex­
pression of both PIM1 and PIM2 kinases (Fig. 4 F). Silvestrol 
had  similar  effects  on  PIM  expression  in  DoHH2  and   
Su­DHL­10 (Fig. 4 G). This is consistent with the known 
short half­life of PIM1 and PIM2 and indicates that PIM ex­
pression is controlled, at least in part, by cap­dependent transla­
tion (Hoover et al., 1997).  This dual effect of translation inhibition 
on PIM and its downstream targets likely accounts for silves­
trol’s dramatic activity against mouse and human lymphomas.
Our study provides new insight into oncogenic kinases in 
human lymphoma. The constitutively active PIM1 and PIM2 
kinases are abundantly expressed across several subtypes of 
NHL, and in follicular lymphoma, PIM positivity identifies 
patients at risk of early relapse and shortened 
survival  and  who  may  require  specific  treat­
ment. Similarly, in DLBCL, PIM1/2 expression 
is associated with the prognostically unfavorable 
ABC subtype (Alizadeh et al., 2000; Rosenwald 
et al., 2003; Wright et al., 2003; Basso et al., 
2005; Poulsen et al., 2005; Lenz et al., 2008;   
Gómez­Abad  et  al.,  2011). Although  clinical 
data on the effect of PIM expression on rapalog 
treatment  are  not  yet  available,  our  data  and 
other  evidence  indicate  that  neither  rapalogs 
nor the newer TOR­kinase inhibitors will be 
and did not cause overt toxicity at an effective dose (0.2 mg/kg, 
d1­7),  consistent  with  published  silvestrol  toxicity  studies, 
showing no major adverse effects at this dose and duration of 
treatment  (Cencic  et  al.,  2009).  In  brief,  animals  bearing   
parental Tsc2­deficient tumors cells (n = 9) remained relapse 
free for up to 3 wk after rapamycin, whereas Eµ-Myc/Tsc2//
Pim2 lymphomas (n = 9) showed no response or relapsed 
early (P = 0.0006; Fig. 4 E). The addition of silvestrol to rapa­
mycin treatment restored rapamycin sensitivity, and Eµ-Myc/
Tsc2/Pim2  tumor­bearing  animals  remained  relapse  free 
for as long as sensitive controls (P = 0.7219; Fig. 4 E). Hence, 
the  translation  inhibitor  silvestrol  has  good  activity  active 
against  human  lymphoma  cells  and  can  overcome  PIM­ 
mediated resistance in vivo.
Translation is required to maintain expression  
of oncoproteins including c-MYC and PIM
In cancer the activation of cap­dependent protein trans­
lation by AKT or PIM ensures the expression of short­lived 
Figure 3.  PIM confers resistance to mTOR inhibi-
tion, but not to genetic blockade of cap-dependent 
translation. (A) Cell viability in vitro comparing rapamycin-
sensitive Eµ-Myc/Tsc2/ lymphomas expressing vector-
GFP, Pim1-GFP, or Pim2-GFP under rapamycin treatment. 
(inset) Enrichment of the Pim2-GFP–expressing subpopu-
lation of Eµ-Myc/Tsc2/ cells upon rapamycin  
exposure in vitro. (B) Immunoblot on lysates of  
Eµ-Myc/Tsc2//vector or Eµ-Myc/Tsc2//Pim2 cells 
treated with vehicle (U) or rapamycin (R), and probed for 
the indicated proteins. (C) Polyribosome profiles gener-
ated from untreated and rapamycin-treated Eµ-Myc/
Tsc2/ and Eµ-Myc/Tsc2//Pim2 tumors, indicating the 
ability of PIM2 to stimulate translation in a partially  
rapamycin-resistant manner (absorbance at 254 nm).  
(D) Enrichment of populations Eµ-Myc/Tsc2/ cells  
expressing vector-GFP (black), Pim2-GFP (orange), and 
eIF4E-GFP (blue) and treated with rapamycin or the  
TOR-kinase inhibitors PP-242 and torin (mean fold 
change and SEM of 5 separate experiments; * indicates 
significance [P < 0.05] vs. vector). (E) Enrichment or loss 
of subpopulations of Eµ-Myc/Tsc2/ and Eµ-Myc/Tsc2//
Pim2 cells engineered to express vector encoding GFP or 
a constitutively active inhibitor of eIF4E (4E-BP1-4A-GFP) 
during culture in vitro (mean results and SEM of three 
separate experiments).1804 Targeting survival signals in lymphoma | Schatz et al.
(Sonenberg and Hinnebusch, 2009). Both kinases can limit 
the effectiveness of chemotherapy, and although the effects of 
AKT are readily reversed by blocking mTORC1 and transla­
tion with rapamycin (Wendel et al., 2004), PIM­expressing 
tumors remain refractory and are able to maintain trans­
lation in an mTORC1­independent manner. However, PIM­ 
expressing tumor cells continue to depend on translational 
activation, and they are therefore sensitive to small molecules 
that directly target the translation initiation complex down­
stream from mTORC1. For example, silvestrol, an inhibitor 
of the eIF4A RNA helicase (Bordeleau et al., 2008), is highly 
active  against  PIM­expressing  tumors  (Fox  et  al.,  2003;   
Hammerman et al., 2005). PIM kinase inhibitors are under 
development, and to date only SGI­1776 has entered phase I 
evaluation. However, its efficacy against multiple tumors and 
lymphoma was limited, and the trial was terminated because 
of  cardiac  toxicity  (SuperGen  press  release  November  10, 
2010). Hence, PIM expression is a significant clinical problem 
in lymphoma and a new therapeutic strategy is needed.
We identify a therapeutic strategy that is highly effective 
against  PIM­expressing  lymphomas.  Both  the  AKT  and   
PIM kinases control regulators of cap­dependent translation 
Figure 4.  The eIF4A helicase inhibitor silvestrol is active against mouse and human lymphomas irrespective of PIM expression. (A) Represen-
tative flow cytometry plots showing enrichment of subpopulations of Pim2-GFP–expressing Eµ-Myc/Tsc2/ upon treatment with vehicle, silvestrol,  
rapamycin, or silvestrol and rapamycin in vitro. (B) Cumulative analysis of three separate experiments showing mean and SEM. (C) Eµ-Myc/Tsc2/  
and Eµ-Myc/Tsc2//Pim2 cells, or 3T3 fibroblasts or VavP-Bcl2/Myc tumor cells were treated with indicated concentrations of silvestrol. Viability was  
assessed after 24 h (mean and SEM of 4 separate assays per cell line). (D) Comparison of cell death induced by silvestrol or two PIM kinase inhibitors  
(SGI-1776, SGI-1773) in a panel of human lymphoma cells (mean of three separate assessments and SEM). (E) Time to relapse in animals bearing  
Eµ-Myc/Tsc2//Pim2 tumors that were treated with rapamycin (red; n = 9) or rapamycin and silvestrol (green; n = 9), or mice bearing parental  
Eµ-Myc/Tsc2/ tumors treated with rapamycin (black dotted line; n = 9). (F and G) Immunoblot on human lymphoma cells Granta-519 (F) or DoHH2  
and Su-DHL-10 (G) treated with vehicle (DMSO), the PIM inhibitor SG-1776, or silvestrol.JEM Vol. 208, No. 9  1805
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In vivo treatment studies. Treatment studies with doxorubicin and/or   
rapamycin were as previously described (Wendel et al., 2004; Mavrakis et al., 
2008). In brief, 106 primary lymphoma cells were injected into the tail vein 
of  10–12­wk­old  female  C57BL/6  mice.  Upon  the  formation  of  well­ 
palpable tumors, the animals were treated with rapamycin (LC Laboratories; 
4 mg/kg, i.p.), doxorubicin (Sigma­Aldrich; 10 mg/kg, i.p.), or a combina­
tion of both. Eµ-Myc/Arf / tumors, which are homogeneous in respect to 
p53 status, were used as controls where indicated. For treatment studies with 
Eµ-Myc/Tsc2/ tumor cells, 10–12­wk­old female C57BL/6 mice were   
injected with 250,000 tumor cells. Rapamycin was given as above, and silves­
trol was dosed as previously described (Bordeleau et al., 2008), given at   
0.2 mg/kg daily for 7 d. After treatment, the mice were monitored by palpa­
tion  and  blood  smears  stained  with  Giemsa  (Thermo  Fisher  Scientific).   
Tumor­free and OS data were analyzed in the Kaplan­Meier format using 
the log­rank (Mantel­Cox) test for statistical significance.
Cell culture, competition, and viability assays. Eµ-Myc/Tsc2/ and 
Eµ-Myc/p53/ tumor cells were cultured in B cell media (1:1 DMEM/
IMDM, with 10% fetal bovine serum, penicillin/streptomycin, and l­glutamine) 
on feeder layers consisting of irradiated NIH­3T3 cells. Competition assays 
used the MSCV­IRES­GFP vector ± the indicated genes (Pim1, Pim2, and 
eIF4E) or the shRNA vector MLP (Mavrakis et al., 2008) for shBad (see   
below). GFP expression was assessed through FACS analysis (Guava EasyCyte; 
Millipore). Experiments were repeated three or more times and averaged 
based on fold change in the percentage of GFP+ cells before and after treat­
ment with drug or vehicle. In competition time point experiments, cells were 
treated with drug or vehicle on day 0 for 24 h and tracked for GFP expres­
sion daily. Human lymphoma cell lines were cultured in RPMI­1640 or 
DME supplemented with 10% fetal bovine serum, penicillin/streptomycin, and 
l­glutamine. Cell viability was assessed with CellTiter­Glo reagent (Promega). 
IC50 values were determined from viability curves and represent a mean value 
from 3–4 curves per cell line. The 4E-BP1­4A (in MSCV­IRES­GFP) vector 
was a gift from the laboratory of N. Rosen (Sloan­Kettering Institute, New 
York, NY) and was sequence confirmed to contain mutation to alanine at resi­
dues T37, T46, S65, and T70. Cytokine stimulation was performed for 6 or   
12 h with 400 pg/ml recombinant mouse IL­3 (Fitzgerald Industries) and   
10 ng/ml recombinant mouse IL­6 (Fitzgerald Industries). Puromycin selec­
tions were performed for 2 d at a concentration of 2 µg/ml.
In vitro treatment studies. Rapamycin (LC Laboratories) was dissolved in 
ethanol vehicle and stored as 10 mM stock solution protected from light at 
20°C. It was diluted in ice­cold ethanol before use at the indicated concen­
trations in the results and compared with 1:1,000 ethanol­treated vehicle 
controls. Silvestrol was stored as 10­mM stock solution in DMSO at 80°C 
and diluted in DMSO before use at the indicated concentrations in the re­
sults. SGI­1773 and SGI­1776 were provided by SuperGen Inc. and were 
stored as 10­mM stock solutions in DMSO at 20°C. Comparisons for sil­
vestrol and the Pim­kinase inhibitors were to 1:1,000 DMSO­treated vehicle 
controls. For detecting drug effects by immunoblot, cells were treated with 
10 nM rapamycin for 4 h, 10 nM silvestrol for 24 h, or 10 µM SGI­1773   
for 24 h.
Polysomal profiling. Sucrose density gradient centrifugation was used to 
separate the ribosome fractions. 15 min before collection, cycloheximide 
(100 µg/ml) was added to the culture medium. Cells were washed in ice­cold 
PBS containing 100 µg/ml cycloheximide and harvested. Cell pellets were 
resuspended in polysome lysis buffer (5 mM Tris­HCl, pH 7.5, 2.5 mM 
MgCl2, 1.5 mM KCl, 2 mM DTT, 0.5% Triton X­100, 0.5% sodium deoxy­
cholate,  100  µg/ml  cycloheximide,  RNAsin  inhibitor,  and  protease  and 
phosphatase inhibitors). Cells were incubated on ice for 15 min, and then 
centrifuged at 10,000 g for 10 min at 4°C. The supernatant (2 mg of protein) 
was layered on a prechilled 10–50% linear sucrose gradient prepared in 5 mM 
Tris­HCl, pH 7.5, 2.5 mM MgCl2, and 1.5 mM KCl, and then centrifuged 
in a Beckman SW41Ti rotor at 35,000 rpm for 2.5 h at 4°C. Gradients were 
fractionated while monitoring absorbance continuously at 254 nm with a 
effective  against  PIM­expressing  human  and  mouse  lym­
phoma cells and far superior to current PIM kinase inhibitors. 
Therapeutic blockade of translation affects several short­lived 
oncoproteins,  including  the  PIM1/2  kinases  and  c-MYC, 
MCL1, and Cyclin D1. Silvestrol does not cause the feedback 
activation of upstream signaling molecules that has been seen 
upon rapamycin treatment (O’Reilly et al., 2006). In sum­
mary, PIM kinase expression adversely affects outcomes in 
NHL, and targeting the translation of oncoproteins like PIM 
and c­Myc effectively disables this critical output of converg­
ing oncogenic pathways.
MATERIALS AND METHODS
TMAs. TMAs were constructed from paraffin­embedded tumor cores of 
452 NHL patients treated at MSKCC since the mid­1980s (173 DLBCL, 
205 FL, 37 MCL, and 37 CLL/SLL). Use of tissue samples was approved by 
the Institutional Review Board and the Human Biospecimen Utilization 
Committee. All cancer biopsies were evaluated at MSKCC, and the histolog­
ical diagnosis was based on hematoxylin and eosin (H&E) staining. TMAs 
were constructed, stained, and scored as previously described (Hedvat et al., 
2002) with antibodies against Pim1 and Pim2 (Cell Signaling Technology). 
Pim1 polyclonal antibody staining was performed at 1:100 dilution using the 
manufacturer’s protocol, with secondary staining by OmniMap DAB anti­
Rb Detection kit (Ventana). Pim2 monoclonal antibody staining was per­
formed manually at 1:100 dilution in citric acid, pH 6, with rabbit secondary 
antibody and finished with DAB (3,3­Diaminobenzidine). All TMA scoring 
was performed by an expert lymphoma hematopathologist.
Clinical data and analyses. Under MSKCC IRB waiver approval, clinical 
data were collected on patients whose tumors appear on the DLBCL and   
FL TMAs. Of the FL cases, we identified 66 whose disease required treat­
ment, whose specimen on the TMA was from before their initial therapy, and 
for whom treatment data and Pim scores were available. These cases were 
subjected to Kaplan­Meier TTE and OS analyses from initiation of therapy 
and date of diagnosis, respectively. Events were defined as progression of dis­
ease, death, or secondary malignancy. Log­rank analysis was used to compare 
groups. The same analyses were performed on 116 DLBCL patients with 
available treatment data and whose biopsy sample on the TMA was from be­
fore initial therapy. PIM+ versus PIM patient groups were compared for 
age, sex, and additional clinical variables listed in Tables S1 and S2 based on 
data availability. 2 or fisher’s exact test was used to compare categorical variables 
and Wilcoxon rank­sum test was used to compare continuous variables.
Mouse  lymphoma  generation  and  analysis. All animal experiments 
were approved by the MSKCC Institutional Animal Care and Use Committee 
in compliance with the U.S. Department of Health and Human Services Guide 
for the Care and Use of Laboratory Animals. The Eµ-Myc model of aggressive 
lymphoma (Adams et al., 1985) and the VavP­Bcl2 model of follicular lym­
phoma (Egle et al., 2004) were adapted to the transplantation approach using 
retrovirally transduced HPCs (Wendel et al., 2004). In brief, we isolated 
HPCs from the fetal livers of day 13.5–14.5 transgenic embryos and infected 
them with retroviral constructs coexpressing GFP and murine Pim2 or con­
stitutively active myristoylated AKT using the MSCV­IRES­GFP vector. 
The HPCs were then transplanted into syngeneic wild­type C57/B6 recipient 
animals after sublethal irradiation (same day 4.5G + 4.5G). We then tracked 
animals for tumor onset by observation, palpation, and blood smear evalua­
tion. Disease onset data were subjected to Kaplan­Meier analysis and the log­
rank  (Mantel­Cox)  test  for  statistical  significance.  H&E,  Ki67, TUNEL, 
phospho­AKT, phospho­4E­BP1, phospho­S6, Pim2, and surface marker analy­
sis were previously described (Mavrakis et al., 2008). Eµ-Myc/Tsc2/ lym­
phomas are generated by crossing Eµ-Myc+/ mice to Tsc2+/ mice (Mills et al., 
2008). Double heterozygous offspring generate B cell tumors because of loss of 
heterozygosity at the Tsc2 locus, resulting in tumors that can be cultured ex vivo.1806 Targeting survival signals in lymphoma | Schatz et al.
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Density Gradient Fractionation System (Teledyne ISCO). Curves were re­
corded by PeakTrak software (Teledyne Isco) in parallel. Data were replotted 
in Excel (Microsoft).
Western  blot  analysis.  Immunoblots  were  performed  from  whole­cell   
lysates. In brief, 20–50 µg of protein/sample were resolved on SDS­PAGE 
gels  and  transferred  to  Immobilon­P  membranes  (Millipore). Antibodies 
were against human PIM1, human PIM2, AKT, phospho­AKT (S473), ribo­
somal protein S6, phospho­rpS6 (S240/244), 4E­BP1, phospho­4EBP1 (S65), 
eIF4E, phospho­eIF4E (S209), BAD, phospho­BAD (S112), phospho­MDM2 
(S166), CyclinD1 (Cell Signaling Technology); mouse Pim1, mouse Pim2, c-Myc 
(Santa Cruz Biotechnology); MCL1 (Rockland Immunochemicals); and   
­tubulin (Sigma­Aldrich).
shRNA gene knockdown. RNAi knockdown of mouse Bad was per­
formed as previously described (Mavrakis et al., 2008) using the GFP­
coexpressing, puromycin­selectable shRNA vector MLP. Three potential 
shRNAs were generated and tested by infecting FL5­12 cells with them 
or empty MLP vector, purification through puromycin selection, and 
immunoblotting protein lysates for Bad protein levels. Sequences of the 
hairpins were as follows: #1, 5­TGCTGTTGACAGTGAGCGACAG­
GAAGACGCTAGTGCTACATAGTGAAGCCACAGATGTATGTAG­
CACTAGCGTCTTCCTGCTGCCTACTGCCTCGGA–3; #2, 5­TGCT­
GTTGACAGTGAGCGAAAGACGCTAGTGCTACAGATATAGTGA­
AGCCACAGATGTATATCTGTAGCACTAGCGTCTTCTGCCTAC­
TGCCTCGGA­3; #3, 5­TGCTGTTGACAGTGAGCGACTGCAA­
CACAGATGCGACAAATAGTGAAGCCACAGATGTATTTGTCGC­
ATCTGTGTTGCAGCTGCCTACTGCCTCGGA­3.
Online  supplemental  material. Table S1 shows complete TMA scoring.   
Tables S2 and S3 show clinical characteristics of analyzed FL and DLBCL pa­
tients, respectively. Tables S4 and S5 show statistical analyses of FL and DLBCL 
patients, respectively, by PIM1 and PIM2 expression. Online supplemental mate­
rial is available at http://www.jem.org/cgi/content/full/jem.20110846/DC1.
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